CN106456738B - 诱导免疫应答的新方法 - Google Patents

诱导免疫应答的新方法 Download PDF

Info

Publication number
CN106456738B
CN106456738B CN201580016665.4A CN201580016665A CN106456738B CN 106456738 B CN106456738 B CN 106456738B CN 201580016665 A CN201580016665 A CN 201580016665A CN 106456738 B CN106456738 B CN 106456738B
Authority
CN
China
Prior art keywords
adjuvant
composition
ala
gly
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580016665.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106456738A (zh
Inventor
W.R.小巴卢
A.M.迪迪埃洛朗
R.G.范德莫斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN106456738A publication Critical patent/CN106456738A/zh
Application granted granted Critical
Publication of CN106456738B publication Critical patent/CN106456738B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/015Hemosporidia antigens, e.g. Plasmodium antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588Adjuvants of undefined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201580016665.4A 2014-04-02 2015-04-02 诱导免疫应答的新方法 Active CN106456738B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1405921.6 2014-04-02
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
PCT/EP2015/057424 WO2015150568A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (2)

Publication Number Publication Date
CN106456738A CN106456738A (zh) 2017-02-22
CN106456738B true CN106456738B (zh) 2021-06-29

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580030331.2A Pending CN106456739A (zh) 2014-04-02 2015-04-02 用于诱导免疫应答的新方法
CN201580016665.4A Active CN106456738B (zh) 2014-04-02 2015-04-02 诱导免疫应答的新方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201580030331.2A Pending CN106456739A (zh) 2014-04-02 2015-04-02 用于诱导免疫应答的新方法

Country Status (18)

Country Link
US (3) US10688168B2 (ja)
EP (2) EP3125930B1 (ja)
JP (2) JP6655549B2 (ja)
KR (2) KR20160132115A (ja)
CN (2) CN106456739A (ja)
AR (1) AR099960A1 (ja)
AU (1) AU2015239025B2 (ja)
BE (1) BE1022355B1 (ja)
BR (2) BR112016022787A2 (ja)
CA (2) CA2943007C (ja)
EA (1) EA037405B1 (ja)
ES (2) ES2961840T3 (ja)
GB (1) GB201405921D0 (ja)
IL (1) IL247493B (ja)
MX (3) MX2016012982A (ja)
SG (1) SG11201607086QA (ja)
WO (2) WO2015150568A1 (ja)
ZA (1) ZA201605955B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) * 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
BR112019025193A2 (pt) 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP3980044A1 (en) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponin purification
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675068A (zh) * 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 新的方法和组合物
CN101678096A (zh) * 2007-04-20 2010-03-24 葛兰素史密丝克莱恩生物有限公司 水包油乳液流感疫苗

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
PL376792A1 (pl) 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
KR20070104881A (ko) 2004-10-14 2007-10-29 크루셀 홀란드 비.브이. 말라리아 프라임/부스트 백신
DK2457926T3 (da) * 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
NO2315597T3 (ja) * 2008-07-25 2018-01-20
AU2009273130B2 (en) * 2008-07-25 2014-10-16 Glaxo Group Limited Novel compositions and methods
HUE039159T2 (hu) * 2008-07-25 2018-12-28 Glaxosmithkline Biologicals Sa Tuberkulózis Rv2386c protein, ezt tartalmazó készítmények és ezek alkalmazása
MX2012008790A (es) * 2010-01-27 2012-08-17 Glaxosmithkline Biolog Sa Antigenos de tuberculosis modificados.
CN103260642B (zh) * 2010-12-14 2018-03-16 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
EP3134116B1 (en) * 2014-04-24 2019-04-03 Statens Serum Institut New m.tuberculosis vaccines
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675068A (zh) * 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 新的方法和组合物
CN101678096A (zh) * 2007-04-20 2010-03-24 葛兰素史密丝克莱恩生物有限公司 水包油乳液流感疫苗

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A PRELIMINARY EVALUATION OF A RECOMBINANT CIRCUMSPOROZOITE PROTEIN VACCINE AGAINST PLASMODIUM FALCIPARUM MALARIA;STOUTE,J.A.等;《The New England Journal of Medicine》;19970109;第336卷(第2期);第87页左栏第二段 *
STOUTE,J.A.等.A PRELIMINARY EVALUATION OF A RECOMBINANT CIRCUMSPOROZOITE PROTEIN VACCINE AGAINST PLASMODIUM FALCIPARUM MALARIA.《The New England Journal of Medicine》.1997,第336卷(第2期), *
The development of the RTS,S malaria vaccine candidate: challenges and lessons;W. R. BALLOU;《Parasite Immunology》;20090930;第31卷(第9期);第492页右栏第一段 *

Also Published As

Publication number Publication date
US11951161B2 (en) 2024-04-09
AR099960A1 (es) 2016-08-31
ES2961840T3 (es) 2024-03-14
BR112016022463A2 (pt) 2017-10-10
EP3125929A1 (en) 2017-02-08
CA2943007C (en) 2024-01-09
GB201405921D0 (en) 2014-05-14
EP3125930B1 (en) 2020-12-02
BE1022355A1 (fr) 2016-02-16
MX2016012982A (es) 2016-12-07
CN106456738A (zh) 2017-02-22
US20170136110A1 (en) 2017-05-18
JP6645982B2 (ja) 2020-02-14
EA037405B1 (ru) 2021-03-25
US10688168B2 (en) 2020-06-23
CA2943007A1 (en) 2015-10-08
CN106456739A (zh) 2017-02-22
US20200306353A1 (en) 2020-10-01
BR112016022787A2 (pt) 2018-03-27
ES2853773T3 (es) 2021-09-17
WO2015150568A1 (en) 2015-10-08
EP3125929C0 (en) 2023-11-01
CA2943711A1 (en) 2015-10-08
ZA201605955B (en) 2019-04-24
MX2016012932A (es) 2016-12-07
SG11201607086QA (en) 2016-09-29
BE1022355B1 (fr) 2016-03-26
IL247493B (en) 2022-08-01
AU2015239025B2 (en) 2018-01-25
AU2015239025A1 (en) 2016-09-22
EA201691638A1 (ru) 2017-04-28
US10624961B2 (en) 2020-04-21
KR20160132115A (ko) 2016-11-16
EP3125929B1 (en) 2023-11-01
US20170112914A1 (en) 2017-04-27
KR20230075525A (ko) 2023-05-31
JP6655549B2 (ja) 2020-02-26
IL247493A0 (en) 2016-11-30
EP3125930A1 (en) 2017-02-08
MX2022013912A (es) 2022-12-13
EP3125929B8 (en) 2023-12-27
JP2017511324A (ja) 2017-04-20
WO2015150567A1 (en) 2015-10-08
JP2017511327A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
US11951161B2 (en) Methods for inducing an immune response
JP5486802B2 (ja) 抗マラリアワクチン
US11679153B2 (en) Methods for inducing an immune response
AU2012257771B2 (en) Vaccine against Streptococcus pneumoniae
US11583578B2 (en) Plasmodium falciparum recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery
BE1022950B1 (fr) Procedes d'induction d'une reponse immunitaire
BE1022373B1 (fr) Nouveaux vaccins antipaludeens

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment